In Q2 2025, Pfizer reported notable revenues from key oncology drugs: The increasing demand for drugs like Padcev and the introduction of new therapies such as Elrexfio, which generated $85 million in ...

As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

Sun Pharmaceutical Industries Ltd tanked 2.41 per cent to Rs 1,616.80. Sai Life, Zydus Life, Pfizer declined 2-4 per cent.

Even as Indian equities tripled investor wealth post-pandemic, several marquee stocks—from paints to pharma and banks—are ...

Pfizer stock is undervalued with strong non-COVID growth, robust Q2 2025 results, and strategic R&D pivots. See more on PFE ...

The Washington State Employment Security Department has said that 100 workers are affected by Pfizer’s (NYSE:PFE) layoff, ...

Companies have claimed improvements to yield, batch consistency and output while acknowledging the risks and challenges ...

Asian shares are lower following a broad decline on Wall Street that reversed some of the big gains from last week ...

Pfizer has urged a Florida federal judge to dismiss lawsuits claiming its birth control shot Depo-Provera can cause users to ...

The Trump administration will move to pull the COVID vaccine off the U.S. market “within months,” one of Robert F. Kennedy Jr ...

The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Pfizer's diversified pipeline and new product launches are driving operational growth. Click here to read more about PFE ...